Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **paclitaxel**, a chemotherapy drug that works by inhibiting cell division, and **serplulimab**, a novel humanized anti–programmed death-1 (PD-1) antibody used in immunotherapy to enhance the body's immune response against cancer cells. The combination is used to treat various cancers, including advanced cervical cancer and other PD-L1 positive tumors, by synergistically targeting both the tumor cells directly and the immune system to fight cancer.
02
Targets
MicrotubulePDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on paclitaxel + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + serplulimab.